Clinical trial · Interventional
Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors
NCT02691078CI-TRIAL-00085489completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Evaluation of the properties of the image capture test using 99m Tc - HYNIC -TOC EDDA (octreotide labeled with 99mTc) for the diagnosis of neuroendocrine tumors compared to the 111In - DTPA-octreotide.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuroendocrine Tumors | Neuroendocrine Tumor | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 99m Tc - HYNIC -TOC EDDA and 111In - DTPA-octreotide | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Adult patients with neuroendocrine tumors
- interventionNames
- Other: 99m Tc - HYNIC -TOC EDDA and 111In - DTPA-octreotide
Primary outcomes (1)
- measure
- Analysis of the images captured with 99m Tc - HYNIC -TOC EDDA ( octreotide labeled with 99mTc ) and 111In - DTPA-octreotide for the diagnosis of neurocrine tumors
- timeFrame
- Up to 30 days
Secondary outcomes (2)
- measure
- Visualization of the ocurrence of the neuroendocrine tumor lesions with both radiopharmaceutical agents
- timeFrame
- Up to 30 days
- measure
- Number of neuroendocrine tumor lesions visualized with both radiopharmaceutical agents
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with histological diagnosis of neuroendocrine tumors * Patients with indication for the staging exam with 11In * Patients diagnosed in any tumor stage * Patients with \> 18 years * Male and female patients * Patients not receiving somatostatin analogues for at least 1 month before image capturing Exclusion Criteria: * Pregnant women * Patients with previous tumor resection of the primary tumor without metastatic disease
References
Publications (1)
- RESULTMoriguchi-Jeckel CM, Madke RR, Radaelli G, Viana A, Nabinger P, Fernandes B, Gossling G, Berdichevski EH, Vilas E, Giacomazzi J, Rocha MS, Borges JA, Hoffmann E, Greggio S, Venturin GT, Barrios CH, Zaffaroni F, Werutsky G, da Costa JC. Clinical validation and diagnostic accuracy of 99mTc-EDDA/HYNIC-TOC compared to 111In-DTPA-octreotide in patients with neuroendocrine tumours: the LACOG 0214 study. Ecancermedicalscience. 2023 Jul 26;17:1582. doi: 10.3332/ecancer.2023.1582. eCollection 2023. PMID 37533941